Clinical trial · Interventional
Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Glucagon has been used for decades as a test of growth hormone (GH) reserve. The pathway by which GH is stimulated by glucagon is not established. Acyl ghrelin has been shown to increase GH levels and to be stimulated by an increase in adrenergic activity. The proposed study will test the concept that with the fall in blood glucose it is likely that there is a sympathetic discharge which contributes to the increase in acyl ghrelin and indirectly leads to the increase in GH and cortisol.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Healthy | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atenolol | Drug | — | UNRESOLVED |
| Glucagon | Drug | — | UNRESOLVED |
| Placebo | Drug | — | UNRESOLVED |
| Saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- type
- OTHER
- label
- Saline s.c. injection and placebo tablet
- description
- Saline s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
- interventionNames
- Drug: Saline
- Drug: Placebo
- type
- OTHER
- label
- glucagon s.c. injection and placebo tablet
- description
- 1 mg glucagon s.c. injection and one placebo tablet (preceded by one placebo tablet per day at 0900h for two days before admission).
- interventionNames
- Drug: Glucagon
- Drug: Placebo
- type
- OTHER
- label
- Saline s.c. injection and atenolol tablet
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 30 Years
Show eligibility criteria text
Inclusion Criteria: 1. Healthy normal men 2. Age 18-30 yrs 3. BMI 18-27 kg/m2 Exclusion Criteria: 1. Medication or previous surgery known to affect ghrelin secretion. 2. Medications known to have an impact on body weight (Seroquel, tricyclic antidepressants). 3. Medications known to have an impact on the beta adrenergic system. 4. Coronary artery disease, congestive heart failure, peripheral vascular disease, diabetes mellitus, significant hypertension (BP \>180 systolic or \>100 diastolic at rest); renal, hepatic, pulmonary disease; untreated hypothyroidism, untreated hyperthyroidism; history of seizure disorder; history of malignancy (other than some skin cancers), history of active chronic infections (e.g., HIV, tuberculosis). 5. Endocrine disorders, i.e., pheochromocytoma, adrenal insufficiency 6. Hematocrit \< 41% men 7. History of daily tobacco use within past 3 months 8. Chronic alcohol abuse by history 9. Weight not stable (more than 10% weight change or more over past 6 months) 10. Strenuous exercise for average of more than 60 min/day 11. Investigational drug within past 6 weeks 12. Psychiatric history especially eating disorders 13. Transmeridian travel within 2 weeks prior to or during study 14. Known hypersensitivity to beta-blockers 15. Estimated Glomerular Filtration Rate below 60 mL/min/1.73m2. 16. Known cardiac dysrhythmia, especially first degree heart block. -
References
Publications (0)
Data not yet available